This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACST Acasti Pharma (ACST) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acasti Pharma Stock (NASDAQ:ACST) 30 days 90 days 365 days Advanced Chart Get Acasti Pharma alerts:Sign Up Key Stats Today's Range$3.03▼$3.1450-Day Range$2.56▼$3.6052-Week Range$1.98▼$3.60Volume12,261 shsAverage Volume22,722 shsMarket Capitalization$29.23 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More… Acasti Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreACST MarketRank™: Acasti Pharma scored higher than 34% of companies evaluated by MarketBeat, and ranked 782nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAcasti Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcasti Pharma has received no research coverage in the past 90 days.Read more about Acasti Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Acasti Pharma are expected to grow in the coming year, from ($1.11) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acasti Pharma is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acasti Pharma is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcasti Pharma has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ACST. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcasti Pharma does not currently pay a dividend.Dividend GrowthAcasti Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ACST. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Acasti Pharma this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acasti Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders13.51% of the stock of Acasti Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.08% of the stock of Acasti Pharma is held by institutions.Read more about Acasti Pharma's insider trading history. Receive ACST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ACST Stock News HeadlinesGrace Therapeutics Reports Promising Drug Development ProgressJune 23, 2025 | tipranks.comGrace Therapeutics Announces Private Placement Financing of up to $30 MillionFebruary 10, 2025 | tmcnet.comBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now. | Crypto 101 Media (Ad)Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists ConferenceDecember 4, 2024 | markets.businessinsider.comAcasti Pharma changes name to Grace TherapeuticsOctober 26, 2024 | msn.comAcasti Announces Corporate Name Change to Grace Therapeutics, Inc.October 25, 2024 | globenewswire.comCraig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)September 27, 2024 | markets.businessinsider.comAcasti Pharma, Inc.: Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104September 25, 2024 | finanznachrichten.deSee More Headlines ACST Stock Analysis - Frequently Asked Questions How were Acasti Pharma's earnings last quarter? Acasti Pharma Inc. (NASDAQ:ACST) announced its earnings results on Friday, June, 21st. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.30. When did Acasti Pharma's stock split? Shares of Acasti Pharma reverse split before market open on Monday, July 10th 2023.The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and CrowdStrike (CRWD). Company Calendar Last Earnings6/21/2024Today6/30/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACST CIK1444192 Webwww.acastipharma.com Phone45-0686-4555Fax45-0687-2272Employees32Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+221.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-13.61% Return on Assets-11.56% Debt Debt-to-Equity RatioN/A Current Ratio7.86 Quick Ratio7.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.57 per share Price / Book0.47Miscellaneous Outstanding Shares9,399,000Free Float8,770,000Market Cap$29.23 million OptionableNot Optionable Beta1.52 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ACST) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.